With the first two CAR-T’s approved, both pending approval in the EU and Kymriah expanding approval in more indications, CAR-T therapies aren’t going anywhere and are set to become mainstream frontline cancer treatments.
BUT as we see success, there are still two key areas for even the leaders to address: European regulations and global distribution. Alongside this, the challenges with improving the underwhelming performance of CAR-TCR therapies in solid tumor indications are more important now than ever before.
With the only promising solid tumor data in TCR approaches, what will the successful future of CAR-T and TCR therapies look like?
The CAR-TCR Summit Europe brings you access to the leaders in this field and the hub of companies creating novel innovations in Europe. We set the stage for visionary leaders to transform the commercial and clinical delivery of cancer therapeutics.
Gain exclusive insight on current clinical programs and case studies on the wave of next generation CAR-TCR candidates from those pioneering in this field.
Focusing on navigating the regulatory minefield, ensuring successful global distribution and successful delivery of CAR-T and TCR therapies, CAR-TCR Summit Europe is your opportunity to network, interact and learn at the only end-to-end meeting that fosters the transformation of leading science to commercial therapies.
"Best focused meeting on CAR and TCR development, from bench to clinic."
-Dominic Justewicz, Associate Research Fellow, Pfizer, CAR-TCR 2017 attendee
"I can't speak highly enough about this conference. This conference allowed me to keep informed of the latest research and development on T cell therapies. I was also able to network with some of the leaders in T cell immunotherapies from both academia and the industry."
-Arnab Ghosh, Hematology & Medical Oncology Fellow, MSKCC, CAR-TCR 2017 attendee